ACNB ACNB CORP Insider Trading

Director Frank Elsner III purchased 5 shares of ACNB at $46.42; stock now down 11.9% in 30 days

Director Frank Elsner III purchased 5 shares of ACNB Corp at $46.42 on March 13, 2026, increasing his holdings from 28,478 to 28,483 shares (net change +0.0% vs pre-transaction holdings). The transaction value was $250.00, a minimal position adjustment. The stock has declined 11.9% over the past 30 days and trades at $46.28, down 13.0% from its 52-week high of $53.18. Reviewing his same-ticker history at ACNB, Elsner's prior 5 buys have produced mixed 90-day outcomes: 3 of 5 achieved positive 90-day returns (well-timed), though his most recent buy on 2025-12-15 showed a 90-day decline of 11.7%. The fundamentals remain solid (annual revenue growth +45.1%, P/E 12.61), but the recent price weakness and small transaction size limit the signal strength of this particular purchase.

Director Frank Elsner III buys 4 shares of ACNB at $52.64; stock now at $52.85, up 15.2% in 30 days.

Director Elsner purchased 4 shares at $52.64 on 2025-12-15, a nominal transaction value of $250.00 that increases his holdings to 28,173 shares. The purchase occurs near the 52-week high of $52.85, with the stock having risen 15.2% over the past 30 days and 14.8% over the past 90 days. Elsner's prior four purchases at ACNB showed strong 90-day performance (three posting gains of 15.2%, 10.3%, and 10.3% respectively), though the transaction size here—just 4 shares—is immaterial relative to his existing 28.2K-share position and does not represent a meaningful portfolio action. The company reports solid fundamentals with $50.9M quarterly revenue, $14.9M net income, and 14.9% annual revenue growth at a reasonable P/E of 16.72, providing operational context for the purchase but not explaining the minimal transaction size.

Director Kelley Scott L bought 396 shares of ACNB at $40.00 on 2025-11-20; prior same-ticker buys achieved +19.0% and +24.9% 90d returns.

Kelley Scott L purchased 396 shares at $40.00, adding 1.5% to his 27.0K share position at ACNB. His prior two open-market purchases at this ticker (2023-08-21 and 2023-09-07) both achieved strong 90-day returns of +19.0% and +24.9% respectively, establishing a pattern of well-timed entry points at ACNB. The current stock price of $48.61 sits at the 52-week high, having gained 9.5% over the past 30 days and 4.3% over 90 days. ACNB's fundamentals remain solid with annual revenue growth of +14.9%, a P/E of 15.38, and a net income of $14.9M on quarterly revenue of $50.9M. The combination of the director's historical accuracy at this specific ticker and the stock's proximity to its 52-week high suggests continued conviction, though current valuation offers less margin of safety than his prior entry points.

Director Lott James J bought 250 ACNB shares at $44.83; now holds 18,290 shares (+1.4% vs prior holdings)

Lott James J, a Director of ACNB CORP, purchased 250 shares at $44.83 on 2025-09-15 for $11,250.00, increasing his holdings from 18,039 to 18,290 shares. The purchase occurred approximately $0.28 below current price ($45.11) and well within the 52-week range ($36.69–$50.72), representing a modest 1.4% increase to his position. ACNB's fundamentals show solid growth: $50.3M in latest quarterly revenue, $11.6M net income, 14.9% annual revenue growth, and an 18.72 P/E ratio, suggesting stable business performance. The transaction is modest in absolute terms relative to his existing 18.3K share stake and occurs in a company with $472.2M market cap and recent stock momentum (+9.7% over 90 days), but without additional context on the director's prior trading pattern or scheduled plans, the single buy-side activity provides limited actionable signal.

Director Frank Elsner III purchases 5 shares of ACNB at $44.83; price now $45.11 (+2.3% in 30 days), 4 of 5 prior buys well-timed.

Frank Elsner III, a Director of ACNB CORP, purchased 5 shares at $44.83 on 2025-09-15 for a total value of $258.49, increasing his holdings from 27,942 to 27,947 shares. The transaction is modest in scale (0.0% change to pre-transaction holdings) and involves only a small dollar amount. Examining his prior trades at ACNB specifically, the insider has demonstrated consistent long-term timing: 4 of his 5 prior buys at this ticker were well-timed at the 90-day mark, with the most recent June 2025 purchase showing +4.6% in 30 days and +10.3% in 90 days. The current stock price of $45.11 is up 2.3% over 30 days and up 9.7% over 90 days, positioning within the 52-week range of $36.69–$50.72. Given the small transaction size and the absence of any significant change to his overall position, this purchase reflects a routine equity accumulation rather than a material signal of conviction.

Director Frank Elsner III purchased 6 shares of ACNB at $40.96; stock down 8.4% in 30 days, down 20.6% from 52-week high.

Director Elsner purchased just 6 shares for $250.00, a transaction of negligible size that increased his holdings from 27,687 to 27,693 shares (net change: +0.0% vs pre-transaction holdings). The current stock price of $40.29 is down 8.4% over the past 30 days and off 20.6% from the 52-week high of $50.72. Across Elsner's prior five purchases at ACNB, his timing has been mixed: 3 of 5 prior buys showed positive 90-day returns (buy on 2024-06-14: +35.4%, buy on 2024-09-13: +10.3%), but 2 of 5 produced negative 90-day returns (buy on 2024-12-13: -11.4%, buy on 2024-03-15: -10.5%). The company reported recent net income of $-272.0K against revenue of $43.5M, with annual revenue growth of +14.9% and a P/E of 17.00. The transaction's minimal size and value limit its informational weight as a directional signal.

Director Frank Elsner III buys 6 shares of ACNB at $41.75; holds 27,417 shares post-transaction

Frank Elsner III, a Director, purchased 6 shares of ACNB at $41.75 on 2025-03-14, a minimal addition to his position of 27,411 shares. The transaction value of $252.88 and insignificant share count increase (+0.0% vs pre-transaction holdings) indicate this is a routine, non-material trade. His same-ticker trade history shows mixed timing outcomes: 2 of 5 prior buys achieved positive 90-day returns, most recently a buy on 2024-06-14 that returned +35.4% over 90 days, but his most recent buy on 2024-12-13 declined -19.4% over 30 days. The stock is currently trading 17.4% below its 52-week high at $41.89, and fundamental metrics show reasonable valuation with a P/E of 14.96 and revenue growth of +14.9%, but the modest transaction size and flat percentage change in holdings provide limited signal about directional conviction.

Director Elsner buys 5 shares of ACNB at $45.55; stock down 15.5% from 52-week high of $50.72.

Director Frank Elsner III purchased 5 shares at $45.55 on 2024-12-13, a nominal transaction adding only 0.0% to his 27.1K-share position. The purchase occurred when ACNB's stock was trading 15.5% below its 52-week high of $50.72 and down 7.5% over the preceding 30 days. While Elsner's prior trades at ACNB show mixed timing—3 of 5 prior buys were well-timed at the 90-day mark, including a June 2024 purchase that returned +21.5% in 30 days and +35.4% in 90 days—the current transaction's minimal size (5 shares, $250 total value) and negligible impact on holdings suggest this is routine activity rather than a material signal. The company's valuation (P/E 12.50, $366.5M market cap with $7.2M net income) appears reasonable, but the transaction's scale and composition warrant observation rather than immediate action.

HELT JAMES (CEO) bought 54 shares of ACNB at $45.55; stock down 15.5% from 52-week high, 3 of 5 prior insider buys at ticker well-timed at 90-day mark.

CEO James Helt purchased 54 shares at $45.55, a modest $2,500 transaction that increased his holdings to 34,749 shares (+0.2%). The stock has declined sharply, trading at $42.87 current price, -15.5% from its 52-week high of $50.72. Within Helt's prior transaction history at ACNB specifically, 3 of 5 previous buys proved well-timed at the 90-day horizon, suggesting some discriminatory buying behavior. However, the stock has continued to drift downward since this December 13 purchase—down 7.5% in 30 days and only -2.6% in 90 days—indicating price momentum remains weak despite the insider's continued accumulation. The valuation metrics are modest (P/E of 12.50), which may provide some margin of safety, but the recent share purchase occurs against a backdrop of sustained relative underperformance and requires monitoring to determine whether this reflects genuine conviction or routine positioning by the CEO.

Director Frank Elsner III purchased 5 shares of ACNB at $42.10, raising holdings to 26,909 shares (26.9K shares).

Frank Elsner III, a director of ACNB Corp, purchased 5 shares on 2024-09-13 for a total transaction value of $250.00, representing a trivial addition to his existing position of 26,903 shares. The transaction amount and incremental share count (+0.0% vs pre-transaction holdings) indicate routine activity rather than material accumulation. Stock has gained 6.6% in the 30-day period and 35.5% over 90 days, trading at $42.88 currently versus the purchase price of $42.10. The company trades at a P/E of 11.75 with net income of $11,279,000.00 and market cap of $366,436,571.52. At the same-ticker history level, Elsner's prior 5 purchases at ACNB show mixed outcomes: two delivered strong 90-day gains (21.5% on 2024-06-14 and 36.1% on 2023-09-15), while three produced losses over the same window. This micro-purchase does not material shift his portfolio exposure or conviction signal.